- Home
- AREN vs TCRX Comparison
AREN vs TCRX Comparison
Compare AREN & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AREN | TCRX |
|---|---|---|
| Founded | 2016 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.6M | 75.1M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AREN | TCRX |
|---|---|---|
| Price | $1.22 | $0.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $8.00 | $7.00 |
| AVG Volume (30 Days) | 101.6K | ★ 442.4K |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 191.93 | 12.28 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $16,892,000.00 | $10,325,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.00 | $19.81 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 27.46 | ★ 266.65 |
| 52 Week Low | $1.21 | $0.88 |
| 52 Week High | $7.85 | $2.57 |
Technical Indicators
Market Signals| Indicator | AREN | TCRX |
|---|---|---|
| Relative Strength Index (RSI) | 30.69 | 37.21 |
| Support Level | N/A | $0.91 |
| Resistance Level | $1.61 | $1.16 |
| Average True Range (ATR) | 0.12 | 0.06 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 7.14 | 11.48 |
Price Performance
Historical ComparisonAbout AREN The Arena Group Holdings Inc.
The Arena Group Holdings Inc is a tech-powered media company that fuses technology, iconic brands, and marketing to deliver vibrant content and experiences that reach million users each month. The company creates robust digital destinations that delight consumers with powerful journalism, news about things such as favorite sports teams, advice on investing, the inside scoop on personal finance, and the latest on lifestyle essentials. The company has four reportable segments: Sports & Leisure, Finance, Lifestyle, and Platform & Other. The company generates revenue from Sports & Leisure. Geographically, the company operates in United States; and Others. It generates maximum revenue from United States.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.